Polifeprosan 20

• CAT Number: I034917
• CAS Number: 90409-78-2
• Molecular Formula: C27H34O10
• Molecular Weight: 518.56
• Purity: 98%
• Synonyms: Polifeprosan 20; Polifeprosan; Polifeprosanum.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (1:1)
• InChI: InChI=1S/C17H16O6.C10H18O4/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;11-9(12)7-5-3-1-2-4-6-8-10(13)14/h2-9H,1,10-11H2,(H,18,19)(H,20,21);1-8H2,(H,11,12)(H,13,14)
• InChIKey: JVYNJRBSXBYXQB-UHFFFAOYSA-N
• SMILES: c1c(ccc(c1)OCCCOc1ccc(cc1)C(=O)O)C(O)=O.C(CCCCCCCCC(=O)O)(O)=O

Polifeprosan 20 (Cat No.: I034917) is a biodegradable copolymer composed of 1,3-bis(carboxyphenoxy)propane and sebacic acid, used primarily as a drug delivery matrix. It is best known for its role in the Gliadel® wafer, which delivers carmustine (BCNU) directly to brain tumors following surgical resection. Polifeprosan 20 enables localized, sustained drug release, reducing systemic toxicity and enhancing therapeutic effectiveness. Its biocompatibility and controlled degradation make it ideal for implantable drug delivery systems, especially in oncology and other applications requiring targeted, site-specific treatment.

Reference

1: Kleinberg L. Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence. 2016 Nov 24;10:2397-2406. eCollection 2016. Review. PubMed PMID: 27920506; PubMed Central PMCID: PMC5125766.
2: Kleinberg L. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid. 2012;7:115-30. doi: 10.2147/CE.S23244. Epub 2012 Oct 26. PubMed PMID: 23118709; PubMed Central PMCID: PMC3484478.
3: Glick JA, Graham RS, Voils SA. Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. Ann Pharmacother. 2010 Jan;44(1):215-8. doi: 10.1345/aph.1M453. Epub 2009 Dec 22. PubMed PMID: 20028954.
4: La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin. 2009 Jan;25(1):149-60. doi: 10.1185/03007990802611935 . Review. PubMed PMID: 19210148.
5: Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18. PubMed PMID: 18636295.
6: Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 1;25(4):399-404. PubMed PMID: 17264335; PubMed Central PMCID: PMC2556256.